Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.43 |
| ▸ | LOX | P28300 | 12/20 | 0.43 |
| ▸ | MET | P08581 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239329 | 0.86 | LOXL2 (0.46) | LOXL2LOXMETKDR | |
| SCHEMBL18249891 | 0.83 | BACE1 (0.39) | METKDR | |
| SCHEMBL20239299 | 0.82 | LOXL2 (0.57) | LOXL2LOX | |
| SCHEMBL20239332 | 0.82 | MET (0.38) | METKDR | |
| SCHEMBL18249887 | 0.72 | MET (0.36) | METKDR | |
| SCHEMBL18249769 | 0.72 | CYP19A1 (0.40) | METKDR | |
| SCHEMBL2640501 | 0.68 | HTR6 (0.44) | LOXL2 | |
| SCHEMBL18249838 | 0.67 | LOXL2 (0.62) | LOXL2LOX | |
| SCHEMBL955244 | 0.67 | PSIP1 (0.48) | LOXL2 | |
| SCHEMBL20239160 | 0.66 | PGR (0.37) | LOXL2LOXMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | LOXL2 2081/4885LOX 2453/4885MET 3407/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | LOXL2 1951/4885LOX 2250/4885MET 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.